MyFinsight
Home
Blog
About
Contact
Total revenues
$58,818K
Net income
$8,654K
Stock-based compensation
expense
$3,456K
Deferred income tax
$2,573K
Accounts receivable, net
-$1,818K
Depreciation and
amortization
$597K
Revenue reserves and
refund liability
$364K
Accrued research and
development
$218K
Right-of-use assets
$135K
Canceled cashflow
$50,164K
Net cash provided by
(used in) operating...
$2,725K
Canceled cashflow
$15,090K
Employee related
expenses
$21,002K
Commercial related
expenses
$7,040K
Outside clinical trial
related expenses
$6,927K
Cost of product sales
$4,606K
Consultants and third-party
services
$4,006K
Other segment items
$3,352K
Provision for income taxes
$3,003K
Interest expense, net
-$228K
Net decrease in
cash, cash...
-$16,169K
Canceled cashflow
$2,725K
Net proceeds from
issuance of common stock...
$321K
Maturities of short-term
investments
$15,945K
Accrued compensation
-$5,905K
Prepaid and other
current and non-current...
$3,792K
Accounts payable
-$2,705K
something is missing
-$1,453K
Inventories
$581K
Other accrued
liabilities
-$339K
Net amortization of
discount on short-term...
$170K
Lease liabilities
-$145K
Net cash (used in)
provided by financing...
-$10,919K
Net cash used in
investing activities
-$7,975K
Canceled cashflow
$321K
Canceled cashflow
$15,945K
Principal payments of term
loans
$7,500K
Repurchases of common stock
in connection with...
$3,740K
Purchases of short-term
investments
$23,920K
Back
Back
Cash Flow
RIGEL PHARMACEUTICALS INC (RIGL)
RIGEL PHARMACEUTICALS INC (RIGL)
source: myfinsight.com